Literature DB >> 23404772

The homo-PADAM protocol: stereoselective and operationally simple synthesis of α-oxo- or α-hydroxy-γ-acylaminoamides and chromanes.

Fabio Morana1, Andrea Basso, Renata Riva, Valeria Rocca, Luca Banfi.   

Abstract

A straightforward and fully stereoselective synthesis of a new class of peptidomimetics, that is α-oxo-γ-acylaminoamides, was achieved starting from various benzaldehydes by a sequence of 1) an asymmetric organocatalytic Mannich reaction, 2) a Passerini multicomponent reaction, 3) an amine deprotection-acyl migration protocol, and 4) a final oxidation. The whole sequence can be performed without purification of the intermediates and represents the first example of a homo-Passerini-amine deprotection-acyl migration (PADAM) strategy. Highly stereoselective reduction of the α-oxo-γ-acylaminoamides afforded α-hydroxy-γ-acylaminoamides as well. In some cases both diastereomers were obtained by simply changing the reducing agent. Finally, starting from protected salicylaldehyde, the same sequence, followed by a Mitsunobu cyclization, afforded highly substituted chromanes.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Year:  2013        PMID: 23404772     DOI: 10.1002/chem.201300023

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  3 in total

1.  Modern Multicomponent Reactions for better Drug Syntheses**

Authors:  Tryfon Zarganes-Tzitzikas; Alexander Dömling
Journal:  Org Chem Front       Date:  2014-09-01       Impact factor: 5.281

2.  Diastereoselective Ugi reaction of chiral 1,3-aminoalcohols derived from an organocatalytic Mannich reaction.

Authors:  Samantha Caputo; Andrea Basso; Lisa Moni; Renata Riva; Valeria Rocca; Luca Banfi
Journal:  Beilstein J Org Chem       Date:  2016-01-26       Impact factor: 2.883

Review 3.  The 100 facets of the Passerini reaction.

Authors:  Luca Banfi; Andrea Basso; Chiara Lambruschini; Lisa Moni; Renata Riva
Journal:  Chem Sci       Date:  2021-09-30       Impact factor: 9.825

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.